Sign in Sign up for free

Last updated: 28 June 2021 at 5:18pm EST

Kevin Churchwell Net Worth



Kevin Churchwell biography

Kevin Churchwell M.D. serves as Independent Director of the Company. He has served as a member of our Board of directors since we commenced operations as an independent company in April 2019. Dr. Churchwell has been the President of Boston Children’s Hospital since September 2018, and executive vice president of health affairs and chief operating officer at Boston Children’s Hospital since August 2013. Before joining Boston Children’s Hospital, Dr. Churchwell was the chief executive officer of Nemours/Alfred I. duPont Hospital for Children from November 2010 to July 2013. Prior to that, Dr. Churchwell was the chief executive officer and executive director for the Monroe Carrell Jr. Children’s Hospital, part of the Vanderbilt University Medical Center, from July 2007 to October 2010. Since 1993, Dr. Churchwell has been a clinician and faculty member at Boston Children’s Hospital and Vanderbilt University Medical Center and was recently appointed the Robert and Dana Smith Associate Professor of Anesthesia at Harvard Medical School. Dr. Churchwell graduated with a B.S. in Biology from the Massachusetts Institute of Technology and received his M.D. from Vanderbilt Medical School.

What is the salary of Kevin Churchwell?

As the Independent Director of Cyclerion Therapeutics, the total compensation of Kevin Churchwell at Cyclerion Therapeutics is $141,253. There are 8 executives at Cyclerion Therapeutics getting paid more, with Andreas Busch having the highest compensation of $3,251,110.



How old is Kevin Churchwell?

Kevin Churchwell is 58, he's been the Independent Director of Cyclerion Therapeutics since 2019. There are 9 older and 5 younger executives at Cyclerion Therapeutics. The oldest executive at Cyclerion Therapeutics, Inc. is George Conrades, 81, who is the Independent Director.

What's Kevin Churchwell's mailing address?

Kevin's mailing address filed with the SEC is C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA, 02142.

Insiders trading at Cyclerion Therapeutics

Over the last 6 years, insiders at Cyclerion Therapeutics have traded over $240,273 worth of Cyclerion Therapeutics stock and bought 4,653,203 units worth $33,009,775 . The most active insiders traders include Peter M Hecht, Mark G Currie, and Terrance Mcguire. On average, Cyclerion Therapeutics executives and independent directors trade stock every 84 days with the average trade being worth of $749,841. The most recent stock trade was executed by Terrance Mcguire on 9 August 2023, trading 8 units of CYCN stock currently worth $27.



What does Cyclerion Therapeutics do?

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.



What does Cyclerion Therapeutics's logo look like?

Cyclerion Therapeutics, Inc. logo

Cyclerion Therapeutics executives and stock owners

Cyclerion Therapeutics executives and other stock owners filed with the SEC include: